Compare Firy Inc. (FIRY) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Firy Inc. trades at $11.27 (market cap $206.28M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 36.5× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Firy Inc. for 13 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FIRY | SYRE | |
|---|---|---|
Market Cap | $206.28M | $7.52B |
Volume | 112,784 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $13.10 | $108.92 |
52-Week Low | $2.28 | $22.18 |
Typical Hold Time | 13 Days | 0 Days |
Enterprise Value | $174.88M | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY (formerly Skillz Inc.) trades at $11.17, down 9.85% in the last session. The technical outlook is bullish based on moving averages, though oscillators are neutral. Fundamentally, the company shows persistent losses with a net income margin of -60.23% despite an 87.76% gross margin. Recent developments include a $719 million legal victory and board additions, but cash burn remains a concern with negative operating cash flow of $68.93 million in 2025.
The outlook is cautious. While the legal win and strategic shifts offer potential upside, sustained losses and negative cash flow pose significant risks. Analyst sentiment is mixed with 60% hold ratings. Key catalysts include the collection of the legal judgment and improved operational efficiency, but investors face substantial execution and liquidity risks.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
